HC Wainwright Lowers Earnings Estimates for DBV Technologies

DBV Technologies S.A. (NASDAQ:DBVT) – Investment analysts at HC Wainwright reduced their FY2027 earnings per share (EPS) estimates for shares of DBV Technologies in a report released on Friday, July 17th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($1.45) per share for the year, down from their previous forecast of ($1.05). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($2.05) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2028 earnings at $1.15 EPS, FY2029 earnings at $3.85 EPS and FY2030 earnings at $6.65 EPS.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.90 million. DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%.

DBVT has been the topic of several other reports. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Guggenheim restated a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a research note on Monday, May 4th. Citizens Jmp lifted their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Weiss Ratings lowered shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Finally, Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $48.50.

DBV Technologies Price Performance

DBV Technologies stock opened at $13.63 on Tuesday. DBV Technologies has a 12 month low of $8.51 and a 12 month high of $26.18. The business has a 50 day simple moving average of $16.79 and a 200-day simple moving average of $19.37. The stock has a market capitalization of $807.03 million, a PE ratio of -3.88 and a beta of -0.95.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Allworth Financial LP acquired a new stake in DBV Technologies in the fourth quarter valued at $32,000. Royal Bank of Canada acquired a new position in shares of DBV Technologies during the 4th quarter worth $34,000. GAMMA Investing LLC increased its holdings in shares of DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares in the last quarter. Truvestments Capital LLC lifted its stake in shares of DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares during the period. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of DBV Technologies in the fourth quarter valued at about $115,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.